Philips launches IntraSight Plus to simplify coronary interventions and advance precision care

Rhea-AI Summary

Philips (NYSE:PHG) launched IntraSight Plus, an interventional cardiology platform cleared by the FDA 510(k) and CE marked for the USA and Europe. The system combines Class IA IVUS, iFR/FFR physiology, co-/tri-registration and real-time device visualization, and claims up to 47% system operation time savings. A first patient case occurred on March 19, 2026, enabling complete revascularization using integrated tri-registered imaging and physiology at the bedside. Commercial availability depends on market release and local regulatory requirements.

Positive

• FDA 510(k) clearance and CE mark for USA and Europe
• Integrated Class IA IVUS with iFR/FFR physiology and tri-registration
• Claims up to 47% system operation time savings vs prior systems

Negative

• 47% time-savings based on a simulated use study, not broad clinical outcomes
• Commercial availability is subject to market release and regulatory requirements

Key Figures

System operation time savings: 47% First case date: March 19, 2026 Two days post-STEMI: 2 days +3 more

6 metrics

System operation time savings 47% Potential time savings for minimally invasive coronary procedures vs. prior setup

First case date March 19, 2026 Date of first patient case using IntraSight Plus in Germany

Two days post-STEMI 2 days Time between acute STEMI and treatment with IntraSight Plus in first case

Three-vessel disease 3 vessels Underlying complex three-vessel coronary artery disease in first reported patient

Single-screen workflow 1 screen Diagnosis, planning, guidance and verification integrated onto one display

FDA clearance type 510(k) Regulatory pathway for IntraSight Plus in the USA

Market Reality Check

Price: $26.72 Vol: Volume 1,351,757 is 1.45x...

normal vol

$26.72 Last Close

Volume Volume 1,351,757 is 1.45x the 20-day average of 929,167, indicating elevated trading interest ahead of/around this news. normal

Technical Shares at $26.72 trade below the 200-day MA of $27.51 and about 20.08% under the 52-week high of $33.435, while sitting roughly 29.67% above the 52-week low of $20.606.

Peers on Argus

PHG slipped 0.3% while key medical device peers were mixed: STE +1.6%, DXCM +0.4...

PHG slipped 0.3% while key medical device peers were mixed: STE +1.6%, DXCM +0.44%, PODD +0.07%, offset by ZBH -0.77% and SNN -0.25%. The lack of a uniform move suggests the IntraSight Plus launch impact was stock-specific rather than a broad sector reaction.

Historical Context

5 past events · Latest: Mar 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	Patent leadership	Positive	-0.3%	Highlighted top medtech patent ranking and strong 2025 R&D investment.
Mar 23	AGM announcement	Positive	+2.1%	Announced AGM agenda with board proposals and dividend-related items.
Mar 23	Board changes	Positive	+2.1%	Proposed new Supervisory Board member and CEO re-appointment.
Mar 17	Consumer campaign	Positive	+0.2%	World Oral Health Night promotion and new Sonicare 6500 claims.
Mar 11	Digital pathology	Positive	-0.5%	Expanded cloud-enabled IntelliSite pathology solution on HealthSuite.

Pattern Detected

Recent innovation and branding announcements have often seen modestly positive reactions, while some R&D or IP milestones have coincided with slight pullbacks, indicating mixed alignment between positive news and short-term price moves.

Recent Company History

Over the past weeks, Philips has highlighted multiple innovation and corporate governance milestones. On Mar 11, it expanded its digital pathology portfolio with a cloud-enabled IntelliSite solution. On Mar 17, a Sonicare oral health campaign underscored consumer-brand positioning. Governance stability was emphasized on Mar 23 with AGM and Supervisory Board/CEO re-appointment proposals, which drew the strongest positive price reactions. On Mar 24, Philips underscored its R&D strength with 1,289 European patent applications. The IntraSight Plus launch continues this theme of platform-based innovation in clinical workflows.

Market Pulse Summary

This announcement highlights Philips’ strategy of integrating imaging, physiology and planning into ...

Analysis

This announcement highlights Philips’ strategy of integrating imaging, physiology and planning into unified platforms. IntraSight Plus, cleared via FDA 510(k) and CE marked, targets coronary interventions with workflow improvements of up to 47% system operation time savings. Recent history shows steady news flow around innovation, patents and digital pathology. Investors monitoring this story may focus on clinical adoption, feedback from early users, and how such platforms contribute to broader revenue and margin trends over time.

Key Terms

percutaneous coronary interventions, fractional flow reserve, 510(k)

3 terms

percutaneous coronary interventions medical

"Interventional cardiologists have traditionally relied on angiography alone for percutaneous coronary interventions (PCI), a common minimally invasive procedure."

Percutaneous coronary interventions are minimally invasive procedures to open narrowed or blocked arteries supplying the heart, typically using a thin tube and a small device such as a balloon or stent inserted through a blood vessel. They matter to investors because demand for these procedures drives sales of medical devices, hospital revenue and related patents or reimbursement policies, so changes in procedure volume, technology or costs can affect healthcare company earnings much like a popular product line does for any business.

fractional flow reserve medical

"Class IA IVUS and instantaneous wave-free ratio/fractional flow reserve (iFR/FFR) physiology, co-registration, tri-registration and real-time device visualization together in one system."

Fractional flow reserve (FFR) is a medical measurement used during heart catheter procedures that compares blood pressure before and after a narrowing in a coronary artery to judge how much that narrowing reduces blood flow. Like checking water pressure before and after a kink in a hose to see if the kink affects flow, FFR tells doctors whether a blockage likely causes chest pain and needs stenting or can be managed conservatively — information that influences demand for diagnostic tools, stents and treatment choices important to investors.

510(k) regulatory

"With CE marking and FDA 510(k) clearance, the redesigned platform combines the most comprehensive diagnostic and treatment planning tools"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. Not financial advice.

March 25, 2026

• Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
• With FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510(k) clearance, the redesigned platform combines the most comprehensive diagnostic and treatment planning tools to deliver efficiency, simplicity and precision in a single intuitive system [1]. By streamlining access to key interventional tools, IntraSight Plus enables clinicians to diagnosis, virtually plan treatment, guide device placement and verify results all on a single screen – supporting confident decision-making and improved patient outcomes.

Interventional cardiologists have traditionally relied on angiography alone for percutaneous coronary interventions (PCI), a common minimally invasive procedure. While guidelines support the use of intravascular ultrasound and physiology for PCI, systems and inputs are often separate, making adoption seem more challenging and less efficient in busy cath labs. IntraSight Plus aims to help with these challenges, bringing everything to the table through a single intuitive system that can help deliver 47% system operation time savings and enable complete control at the bedside [2].

“As more advanced technology is integrated into the cath lab, the need for connectivity between the imaging tools is more important than ever before,” said Stacy Beske, Business Leader Image Guided Therapy Devices at Philips. “IntraSight Plus was built using feedback from our customers and represents a fundamental shift in interventional cardiology – a future driven by integrated intelligence that lets physicians focus on the decision-making that only they can do.”

Innovation that simplifies complex interventions
On Thursday, March 19, 2026, Prof. Dr. Jan-Malte Sinning performed the first patient case using IntraSight Plus at Cellitinnen-Krankenhaus St. Vinzenz in Köln, Germany. The hospital recently renewed its catheterization lab infrastructure with Philips’ Azurion interventional suites. The addition of IntraSight Plus as part of this ecosystem allows for enhanced physician workflow.   

“Modern PCI is becoming increasingly complex,” said Prof. Dr. Sinning. “Intravascular imaging combined with physiology provides the level of detail we need for contemporary PCI. What stands out with IntraSight Plus is that the platform is clearly designed around how we actually work in the cath lab – combining physiology, imaging and decision-making support in a way that fits naturally into the clinical workflow.”

The patient treated in this first case presented with an acute ST-elevation myocardial infarction (STEMI) of the left anterior descending (LAD) artery two days ago and underlying complex three-vessel disease. Using the Philips Azurion interventional platform in combination with the new IntraSight Plus system, Prof. Dr. Sinning performed a complete revascularization prior to discharge.

The integrated tri-registration of angiography, physiological assessment, and intravascular imaging enabled a streamlined and intuitive workflow, allowing treatment to be focused on hemodynamically relevant lesions and ensuring optimal stent deployment to improve patient outcomes.

Delivering precision through integration

A fully redesigned system that merges Philips IntraSight and SyncVision technologies, IntraSight Plus brings Class IA IVUS and instantaneous wave-free ratio/fractional flow reserve (iFR/FFR) physiology, co-registration, tri-registration and real-time device visualization together in one system.

It enables:

• Greater Precision: Class IA IVUS and iFR tri-registered onto one screen so clinicians can see the plaque morphology and its ischemic impact at every point along the vessel. Physicians can plan their PCI, estimate results, size and place stents and perform precise PCIs for better patient care.
• Efficiency: Enter patient data once. Streamlined communication between IntraSight Plus and Azurion DataHandler is designed for customers to spend less time operating multiple technologies.[3]
• Customer Control: The intuitive platform brings procedural guidance and unified control to the bedside, providing complete bedside procedural control without leaving the sterile field.

Philips’ portfolio of image-guided therapy solutions uniquely integrates best in class imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment for even the most complex procedures. Built using a common Philips architecture, IntraSight Plus also connects with the company’s Azurion platform and PACS system for tighter integration within a Philips lab environment.

Availability
IntraSight Plus is FDA 510(k) cleared in the USA and CE marked in Europe. Commercial availability is subject to market release and applicable regulatory requirements.

[1] REF-00942-v1 IntraSight Plus The Most Comprehensive Claim Support
[2] IntraSight Plus Simulated Use Report, D002094363. Data on file at Philips. When compared to IntraSight, SyncVision console and Azurion. Tested in a simulated use study with Philips employees.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips IntraSight Plus
• Philips IntraSight Plus screen
• Team Germany IntraSight

FAQ

What is IntraSight Plus and why did Philips (PHG) launch it on March 25, 2026?

IntraSight Plus is an integrated interventional guidance platform combining imaging and physiology for PCI. According to Philips, it merges Class IA IVUS and iFR/FFR with tri-registration to streamline planning, device placement and bedside control in cath labs.

Is IntraSight Plus cleared for clinical use in the USA and Europe for PHG shareholders?

Yes. According to Philips, IntraSight Plus received FDA 510(k) clearance and a CE mark, enabling clinical use in the USA and Europe pending local market release and applicable regulatory requirements.

How did Philips measure the claimed 47% system operation time savings for IntraSight Plus?

The 47% savings come from a Philips simulated use study comparing IntraSight Plus to prior consoles. According to Philips, the test used simulated workflows with employees and is not presented as broad clinical real-world data.

What clinical evidence supports IntraSight Plus based on the March 19, 2026 first case?

A first-in-use case on March 19, 2026 used IntraSight Plus for complete revascularization in a STEMI patient. According to Philips, integrated tri-registration enabled targeted treatment and optimal stent deployment prior to discharge.

How does IntraSight Plus integrate with Philips’ existing lab systems for PHG customers?

IntraSight Plus connects with Azurion and PACS to support unified control and data flow at the bedside. According to Philips, this integration reduces duplicate entry and streamlines communication within a Philips lab environment.